Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults

NCT06625060 is registered in ClinicalTrials.gov with Ipsen as lead sponsor.

NCT NCT06625060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06625060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults
Lead sponsor
Ipsen
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 10, 2024
Completion date
October 31, 2027
Enrollment
670 (actual)
Sites
162

Conditions

As the registry lists them; a condition with its own page is linked.

chronic migraine, episodic migraine